 |
|
|
| |
INTERFERON (IFN)-FREE COMBINATION TREATMENT WITH THE HCV NS3/4A PROTEASE INHIBITOR FALDAPREVIR (BI 201335) AND THE NON-NUCLEOSIDE NS5B INHIBITOR BI 207127 ± RIBAVIRIN: FINAL RESULTS OF SOUND-C2 AND PREDICTORS OF RESPONSE
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Stefan Zeuzem1, Vicente Soriano2, Tarik Asselah3, Jean-Pierre Bronowicki4, Ansgar W. Lohse5, Beat Müllhaupt6, Marcus Schuchmann7, Marc Bourliere8, Maria Buti9, Stuart Roberts10, Ed Gane11, Jerry O. Stern12, Richard Vinisko12,
Ivona Herichova13, Wulf O. Bocher14, Federico J. Mensa12
1Klinikum der J. W. Goethe-Universität, Frankfurt am Main, Germany; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain; 3Hopital Beaujon, Clichy, France; 4Hopital de Brabois, Vandoeuvre Cedex, France; 5University Hospital Hamburg Eppendorf, Hamburg, Germany; 6University Hospital of Zurich, Zurich, Switzerland; 7University Hospital Mainz, Mainz, Germany; 8Hopital Saint Joseph, Marseille, France; 9Hospital Vall d'Hebron and Ciberehd, Barcelona, Spain; 10Alfred Hospital, Department of Gastroenterology, Melbourne, Australia; 11Auckland Clinical Studies, Auckland, New Zealand; 12Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 13Boehringer Ingelheim Pharma RCV GmbH & Co KG, Vienna, Austria; 14Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
|
| |
|
|
|
|
|
